Study of RET Inhibitor TAS0953/HM06 in Patients With Advanced Solid Tumors With RET Gene Abnormalities

Clinical trial NCT04683250 · RECRUITING

Trial details

NCT number: NCT04683250
Sponsor: Taiho Pharmaceutical Co., Ltd.
Status: RECRUITING
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

RET-altered Non Small Cell Lung Cancer RET-altered Solid Tumors

Start date: 2020-12-16
Primary completion: 2030-03-01
Enrollment: 244

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.